What Nacuity Pharmaceuticals does

Nacuity Pharmaceuticals is a clinical-stage private biopharmaceutical company founded in 2017 and headquartered in Fort Worth, Texas, that develops targeted antioxidant therapies to stop oxidative tissue damage in rare blinding eye diseases and related chronic conditions. The company's proprietary technology platform centers on two small molecules licensed from Johns Hopkins University: NPI-001 (N-acetylcysteine amide, or NACA), a GMP-grade oral tablet that donates cysteine to boost intracellular glutathione biosynthesis and crosses the blood-brain and blood-retinal barriers with approximately three-fold greater efficacy than standard N-acetylcysteine; and NPI-002 (diNACA), a sustained-release intravitreal implant co-developed with Integral Biosystems using its NanoM delivery platform. The company runs five development programs (NP-1 through NP-5) covering retinitis pigmentosa associated with Usher syndrome, cataract progression post-vitrectomy, nephropathic cystinosis, AMD and Stargardt disease, and Hereditary Cystatin C Amyloid Angiopathy (HCCAA), with three Phase 1/2 trials active across Australian clinical sites.

Nacuity's go-to-market motion is entirely clinical-trial-driven at present, with patient access to investigational products limited to trial participation. The lead NPI-001 RP program received FDA Orphan Drug, Fast Track (January 2025), and Breakthrough Therapy Designations (October 2025), and produced Phase 1/2 data in September 2025 demonstrating more than 50% reduction in photoreceptor loss over two years versus placebo. Manufacturing readiness is being built through a $3.2M API contract with IDT Australia and a collaboration with Integral Biosystems for sustained-release implant technology, while Arctic Therapeutics holds exclusive rights to develop NPI-001 (as AT-001) for HCCAA in Iceland and related cerebral amyloid angiopathies worldwide under an EMA-approved protocol. The company is venture-backed by Foundation Fighting Blindness and its RD Fund (which co-led a $16.5M Series B in June 2022), with Johns Hopkins University holding equity from the 2018 IP license; the management team and Scientific Advisory Board draw heavily from former Alcon Laboratories leadership and Johns Hopkins Wilmer Eye Institute faculty. All products remain investigational, no commercial pricing exists, and the company is pre-revenue.

Name

Nacuity Pharmaceuticals

Legal name

Nacuity Pharmaceuticals, Inc.

Website

https://nacuity.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Nacuity Pharmaceuticals is a clinical-stage private biopharma developing NACA-based antioxidant therapies (oral tablets and intravitreal implants) for rare ocular diseases including retinitis pigmentosa, cataract, and cystinosis, currently operating through Phase 1/2 trials with no approved products.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals for Rare Eye Diseases

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

Keywords

• Oxidative stress therapeutics
• Retinitis pigmentosa treatment
• Ophthalmic drug development
• Antioxidant pharmaceuticals
• Rare disease therapies

Headquarters

HQ city

Fort Worth

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Distribution channels3 records

Marketing channels5 records

Core offering

Nacuity Pharmaceuticals develops prescription-grade antioxidant therapeutics that target oxidative stress to treat rare blinding eye diseases and serious chronic conditions. The company's lead clinical assets are NPI-001 (N-acetylcysteine amide oral tablets) for retinitis pigmentosa, nephropathic cystinosis, and Hereditary Cystatin C Amyloid Angiopathy, and NPI-002 (a sustained-release intravitreal implant of diNACA) for delaying cataract progression. Five development programs (NP-1 through NP-5) are progressing through Phase 1/2 clinical trials under FDA Fast Track, Breakthrough Therapy, and Orphan Drug designations.

Product overview

Nacuity Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted antioxidant therapies to stop oxidative tissue damage. The company's product portfolio consists of two lead product candidates: NPI-001 (N-acetylcysteine amide) tablets, an oral formulation for retinitis pigmentosa, cystinosis, and rare neurological diseases; and NPI-002, a sustained-release intravitreal implant for cataract progression. Both products leverage the company's proprietary antioxidant technology platform targeting oxidative stress, with five development programs (NP-1 through NP-5) addressing conditions including retinitis pigmentosa, cataract, nephropathic cystinosis, AMD, Stargardt disease, and HCCAA.

Differentiator

Problem solved

Functional benefit

Products and services

• NPI-001 (N-acetylcysteine amide) Tablets Proprietary GMP-grade oral tablet formulation of N-acetylcysteine amide (NACA) designed to boost intracellular glutathione biosynthesis and stop oxidative tissue damage in patients with blinding eye diseases including retinitis pigmentosa and nephropathic cystinosis, as well as rare neurological conditions such as Hereditary Cystatin C Amyloid Angiopathy.
• NPI-002 Intravitreal Implant Novel sustained-release sterile intravitreal implant delivering diNACA (di-N-acetylcysteine amide) via a precision delivery system with vitreal elution over time. Designed to inhibit oxidative-induced cataract formation in patients undergoing vitrectomy.
• NP-1 Program (Oral NPI-001 for Retinitis Pigmentosa) Development program for an oral small molecule therapy targeting oxidative stress to slow or halt disease progression in retinitis pigmentosa patients with functioning cones, regardless of the underlying genetic mutation.
• NP-2 Program (NPI-002 Implant for Cataract Progression) Development program for a sustained-release intravitreal implant delivering a slow-release antioxidant molecule to slow cataract progression in patients undergoing vitrectomy.
• NP-3 Program (Oral NPI-001 for Nephropathic Cystinosis) Development program investigating NPI-001 oral therapy as a disease-modifying antioxidant treatment for nephropathic cystinosis, with potential for improved compliance over existing unpalatable cysteamine therapies.
• NP-4 Program (Intravitreal Implant for AMD and Stargardt Disease) Development program evaluating intravitreal delivery of NPI-001 or NPI-002 as potential treatments for retinal degenerative diseases including age-related macular degeneration and Stargardt disease.
• NP-5 Program (Oral NPI-001 for Hereditary Cystatin C Amyloid Angiopathy) Development program (licensed to Arctic Therapeutics as AT-001) evaluating oral NPI-001 for treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare neurological disease prevalent in Icelanders, leveraging NPI-001's ability to cross the blood-brain barrier.

Quantifiable outcome

• NPI-001 slowed photoreceptor loss by more than 50% over two years in RP associated with Usher syndrome vs. placebo (Phase 1/2 SLO-RP trial, September 2025 data)
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

22 partnerships are on record, tiered supporting, flagship and core.

• IDT Australia LimitedsupportingTechnology or Integration · 9 April 2025IDT Australia secured a manufacturing contract with Nacuity Pharmaceuticals Pty Ltd for NPI-001, an investigational treatment for retinitis pigmentosa (RP). This $3.2M contract supports recomissioning of Australia's largest small molecule API plant.
• Arctic TherapeuticsflagshipStrategic or Co-development Partner · 13 September 2022Exclusive licensing agreement and strategic partnership for development and commercialization of NPI-001 (as AT-001) for Hereditary Cystatin C Amyloid Angiopathy (HCCAA) in Iceland and related CAAs worldwide. Nacuity provides exclusive rights to Arctic for HCCAA in Iceland; Nacuity and Arctic collaborate on all regulatory approval and development activities. In March 2024, EMA approved the first clinical trial of AT-001 for HCCAA in Iceland.
• Integral BiosystemscoreTechnology or Integration · 13 August 2021Collaboration and License Agreement signed August 2021 to co-develop sustained release products utilizing Nacuity's proprietary antioxidant compounds and Integral's patented NanoM platform ophthalmic insert technology. The collaboration targets several ocular disorders including development of the NPI-002 intravitreal implant for cataract.
• Nanoform Finland PlcsupportingTechnology or Integration · 31 March 2021Technology Proof of Concept (PoC) Agreement signed March 2021 to apply Nanoform's award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity's NPI-001 and NPI-002 drug candidates.
• Johns Hopkins University (Wilmer Eye Institute)coreStrategic or Co-development Partner · 13 June 2018Exclusive worldwide license from Johns Hopkins University to IP underlying patent applications covering treatment of RP with N-acetylcysteine amide and biomarkers. Nacuity previously held non-exclusive rights before upgrading to exclusive license. JHU became a shareholder and is entitled to milestone payments and royalties on clinical development and regulatory approval. The license builds on research from Dr. Peter Campochiaro at the Wilmer Eye Institute involving oxidative stress in the retina.
• Statistics Data CorporationsupportingOthersIndustrial collaborator providing clinical research services. Listed as an industrial collaborator on the Investors & Collaborators page.
• MedPharmsupportingOthersContract research organization specializing in topical and ophthalmic formulations. Listed as an industrial collaborator on the Investors & Collaborators page.
• Eurofins DiscoverysupportingOthersContract research organization providing drug discovery services. Listed as an industrial collaborator on the Investors & Collaborators page.
• Heidelberg EngineeringsupportingOthersMedical device and imaging company providing spectral-domain optical coherence tomography (SD-OCT) technology for clinical trials. Listed as an industrial collaborator on the Investors & Collaborators page.
• CMAX Clinical Trials and ResearchsupportingOthersAustralian-based contract research organization conducting clinical trials. Supports Nacuity's clinical trial operations in Australia.
• PCI Pharma ServicessupportingOthersPharmaceutical contract manufacturing and supply chain services. Listed as an industrial collaborator on the Investors & Collaborators page.
• AcclimesupportingOthersBusiness and regulatory consulting firm supporting Nacuity's operations. Listed as an industrial collaborator on the Investors & Collaborators page.
• BDG SynthesissupportingOthersContract manufacturing organization. Listed as an industrial collaborator on the Investors & Collaborators page.
• University of AucklandsupportingOthersAcademic research institution collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.
• UNT Health Science Center / North Texas Eye Research InstitutesupportingOthersAcademic research institution with North Texas Eye Research Institute collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.
• Howard Hughes Medical InstitutesupportingOthersMedical research institute supporting Nacuity's research. Listed on the Investors & Collaborators page under Academic Research.
• Robert Gordon University AberdeensupportingOthersAcademic institution collaborating with Nacuity on research. Listed on the Investors & Collaborators page under Academic Research.
• University of PennsylvaniasupportingOthersAcademic institution (Dunaieff Lab) collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.
• The Florey Institute of Neuroscience & Mental HealthsupportingOthersAustralian neuroscience research institute collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.
• Baylor College of Medicine (Cullen Eye Institute)supportingOthersBaylor College of Medicine's Cullen Eye Institute, where board member Tim Stout, MD, PhD, MBA serves as Director. Listed as an academic research collaborator on the Investors & Collaborators page.
• The University of Adelaide Ophthalmic Research LaboratorysupportingOthersAustralian academic institution where Nacuity's cataract clinical trial (NP-2) is conducted. Listed as an academic research collaborator on the Investors & Collaborators page.
• Doheny Eye InstitutesupportingOthersProvider of imaging analysis for Nacuity's clinical trials. Listed as an academic research collaborator on the Investors & Collaborators page.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Recordati Rare Diseases: Specialty pharmaceutical company with a dedicated rare disease business including ophthalmology and metabolic disorders. Relevant as a potential commercial partner or acquirer for Nacuity's cystinosis and ophthalmology programs given its established rare disease commercial infrastructure.
• Alcon: Global leader in ophthalmic pharmaceuticals, surgical equipment, and vision care. Multiple Nacuity founders and senior leaders (CEO Halden Conner, CSO Michael Wall, board members Gerald Cagle and Onkar Singh) are former Alcon executives, illustrating the deep domain overlap and the company Alcon represents as a potential strategic acquirer or commercial partner.

Direct peers

• Clearside Biomedical: Clinical-stage ophthalmology company specializing in suprachoroidal drug delivery for retinal diseases. Shares a Scientific Advisory Board member (Gerald Cagle) with Nacuity and competes in the ocular drug delivery space, particularly relevant to Nacuity's NPI-002 intravitreal implant.
• jCyte: Clinical-stage cell therapy company developing jCell, a stem-cell-based treatment for retinitis pigmentosa. Directly competes with Nacuity in the RP indication through a cell-replacement approach versus Nacuity's antioxidant mechanism.
• Opus Genetics: Clinical-stage gene therapy company focused on inherited retinal diseases including retinitis pigmentosa. Shares the same Foundation Fighting Blindness / RD Fund investor backing and Scientific Advisory Board leadership as Nacuity, and competes for the same patient population with a mutation-specific gene therapy approach versus Nacuity's gene-agnostic small molecule.
• Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases including X-linked retinitis pigmentosa. Direct competitor in the RP indication through a different therapeutic modality.
• Atsena Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases including Leber congenital amaurosis and retinitis pigmentosa. Russell Kelley (RD Fund, Nacuity board) is listed as a board observer, indicating shared investor ecosystem and overlapping indication strategy.
• ProQR Therapeutics: Clinical-stage RNA therapeutics company developing Axiomer RNA editing therapies for inherited retinal diseases including Usher syndrome and retinitis pigmentosa. Targets the same RP/Usher syndrome population as Nacuity's lead NPI-001 program through a different (RNA-based) modality.
• SparingVision: Clinical-stage ophthalmology company developing gene therapies for retinitis pigmentosa and other inherited retinal diseases. Directly competes with Nacuity's lead NPI-001 program in the same RP indication, addressing oxidative-stress-related photoreceptor loss through a different (gene therapy) modality.

Emerging players

• Editas Medicine: Clinical-stage gene-editing company developing in vivo CRISPR-based therapies for inherited retinal diseases. Competes in the broader retinal disease space with a transformative modality that could complement or substitute for Nacuity's antioxidant approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nacuity-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nacuity Pharmaceuticals